secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001437749-23-031615
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics reports Q3 net income of $0.5M; cash low, raises $5M
------------------------------------------------------------------------

- Net income $0.5M ($0.06 per share) vs net loss $0.7M in Q3 2022; R&D $0.9M, G&A $1.2M.
- Cash $0.2M at Sep 30, 2023; completed $5M public equity offering in Nov 2023.
- AJ201 Phase 1b/2a enrollment on track; topline data expected Q2 2024.
- BAER-101 preclinical results accepted for AES meeting; IV tramadol Phase 3 design agreed with FDA.
- IV tramadol Phase 3 safety study pending additional financing; aim to start as soon as feasible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/0001437749-23-031615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/atxi20230822_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer